NAVAN Closes Seed Funding Round
Investors include Amgen Ventures, HTGF and Hemi Ventures
17-May-2019 -
NAVAN Technologies, Inc., a privately-held biotechnology company enabling the development of next generation cell and gene therapies through its novel, non-viral NanoStraw platform, announced it had closed a seed investment round led by Amgen Ventures, High-Tech Gründerfonds (HTGF), Hemi ...
cell therapies
gene therapy
seed financing